What are the recommended history taking, clinical examination findings, diagnostic investigations, and management strategies for a patient with suspected cystic fibrosis?

Cystic Fibrosis: Clinical Approach

History

Focus history-taking on respiratory symptoms (chronic cough, recurrent pneumonia, bronchiectasis), gastrointestinal manifestations (steatorrhea, failure to thrive, recurrent pancreatitis), and family history of CF or consanguinity. Key historical elements include:

• Respiratory: Chronic productive cough, recurrent or persistent pneumonia, hemoptysis, nasal polyps, chronic sinusitis
• Gastrointestinal: Meconium ileus at birth, steatorrhea, failure to thrive despite adequate intake, recurrent pancreatitis, distal intestinal obstruction syndrome
• Reproductive: Male infertility (congenital bilateral absence of vas deferens), delayed puberty
• Other: Salty-tasting skin, heat prostration, metabolic alkalosis, digital clubbing onset
• Newborn screening results if available 1

Adults may present atypically with isolated bronchiectasis, chronic sinusitis, pancreatitis, diabetes, or male infertility—the mean age of adult diagnosis is 42 years (range 18-71), with bronchiectasis being the most common prior diagnosis 2.

Clinical Examination

Examine for growth parameters (weight-for-age percentiles), respiratory signs (crackles, wheezing, hyperinflation), digital clubbing, and signs of malabsorption.

Key examination findings:

• Growth: Plot weight, height, and BMI percentiles—downward trajectory suggests malabsorption 1
• Respiratory: Crackles, wheezing, prolonged expiratory phase, hyperinflation, use of accessory muscles, digital clubbing
• Abdominal: Hepatomegaly (cirrhosis), distension, palpable stool (constipation/DIOS)
• Nasal: Polyps on anterior rhinoscopy
• Skin: Assess for salt crystals (rare but pathognomonic)

Investigation

The sweat chloride test remains the gold standard for CF diagnosis—values ≥60 mmol/L confirm CF, while intermediate values (30-59 mmol/L) require further evaluation with CFTR genetic testing. 3, 4

Diagnostic Algorithm:

1. Sweat Chloride Testing (pilocarpine iontophoresis with gauze/filter paper or Macroduct collection):

   • ≥60 mmol/L = CF diagnosis confirmed
   • 30-59 mmol/L = intermediate, requires genetic testing
   • <30 mmol/L = CF unlikely but consider if high clinical suspicion 3

2. CFTR Genetic Testing:

   • Initial: Standard 50-variant panel detects 94% of adult-diagnosed CF cases 2
   • Extended: Full-gene sequencing of coding/flanking regions plus deletion/duplication analysis when <2 disease-causing variants identified 1
   • Intronic region sequencing for CRMS/CFSPID cases 1
   • Every diagnosed CF patient requires genotyping for CFTR modulator eligibility 5

3. Functional Testing (when diagnosis remains unclear):

   • Nasal potential difference measurement
   • Intestinal current measurement
   • Available at expert centers 3

4. Baseline Assessments After Diagnosis:

   • Respiratory culture for CF pathogens (Pseudomonas aeruginosa, Staphylococcus aureus)
   • Chest imaging (CT preferred over radiograph for baseline bronchiectasis assessment)
   • Pulmonary function testing (spirometry) if age-appropriate
   • Pancreatic function (fecal elastase)
   • Fat-soluble vitamins (A, D, E, K)
   • Liver function tests
   • Glucose tolerance testing (OGTT starting age 10)
   • Sputum microbiology 6

Common Pitfall: The 2018 CF Foundation guidelines emphasize that CF remains a clinical diagnosis—genetic testing alone cannot rule out CF if clinical suspicion is high, as >1500 CFTR mutations exist with varying pathogenicity 5, 4.

Management

All CF patients require immediate referral to a specialized CF center for multidisciplinary care, with CFTR modulator therapy initiated based on genotype (97% of adult-diagnosed patients have modulator-treatable variants). 2

Treatment Framework:

1. CFTR Modulator Therapy (Mutation-Specific):

• First-line therapy when genotype-eligible—transforms disease trajectory
• Requires confirmed genotype for selection 5
• 97% of adult-diagnosed CF patients have treatable variants 2

2. Respiratory Management:

• Airway clearance therapy: Daily chest physiotherapy (oscillating positive expiratory pressure devices, high-frequency chest wall oscillation, or manual techniques)
• Inhaled medications:
  • Hypertonic saline (7%) for mucus clearance
  • Dornase alfa (recombinant DNase) for sputum viscosity
  • Inhaled antibiotics for chronic Pseudomonas (tobramycin, aztreonam, colistin)
• Oral antibiotics: For acute exacerbations or prolonged cough >2 weeks 1
• Anti-inflammatory: Azithromycin (chronic suppressive therapy) for anti-inflammatory effects
• Avoid routine corticosteroids: Four guidelines conditionally support oral corticosteroids, six oppose routine inhaled corticosteroids 7

3. Nutritional Management:

• Pancreatic enzyme replacement (if pancreatic insufficient—65% of adult-diagnosed patients) 2
• Fat-soluble vitamin supplementation (A, D, E, K)
• High-calorie, high-fat diet (120-150% of recommended daily intake)
• Dietitian involvement for weight trajectory monitoring 1

4. Monitoring Schedule:

• Quarterly clinic visits minimum at CF center
• Annual assessments: Spirometry, OGTT (age ≥10), liver function, vitamin levels, sputum culture, chest imaging
• Diabetes screening: OGTT annually starting age 10 (CF-related diabetes occurs in 40-50% by adulthood)

5. Complication Management:

• CF-related diabetes: Insulin therapy (oral agents less effective)
• Liver disease: Ursodeoxycholic acid for cholestasis
• Bone disease: Vitamin D optimization, bisphosphonates if osteoporotic
• Male infertility: Assisted reproductive technologies required (>95% have congenital bilateral absence of vas deferens) 8

6. Infection Control:

• Standard CF infection prevention and control guidelines in healthcare settings 1
• Segregation from other CF patients (cross-infection prevention)
• Annual influenza vaccination
• Pneumococcal vaccination

Special Consideration: CRMS/CFSPID

For screen-positive newborns with inconclusive diagnosis (CRMS/CFSPID):

• Annual follow-up with CF clinician minimum until age 8 1
• Repeat sweat chloride at 6 months, then annually until age 8 1
• Selective respiratory cultures at visits (not routine) 1
• Avoid routine labs: No routine vitamin testing, liver function, glucose monitoring, or PFTs 1
• Genetic counseling with trained CF genetics professionals 1
• 10% will convert to CF diagnosis through variant reclassification or rising sweat chloride 1

Critical Pitfall: Disease severity in adult-diagnosed CF is typically milder (mean FEV1 68% predicted) than childhood-diagnosed cases, but patients have often sustained irreversible organ damage (bronchiectasis) before diagnosis 2. Early aggressive treatment with modulators may prevent further decline.

The 2024 CFF guidelines 1 represent the most current evidence-based approach, emphasizing genetic precision, selective monitoring to avoid over-medicalization of CRMS/CFSPID, and the transformative role of genotype-directed CFTR modulator therapy in changing CF from a pediatric terminal illness to a chronic adult disease.